Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation by Amalendu P Ranjan et al.
Ranjan et al. Journal of Nanobiotechnology 2013, 11:40
http://www.jnanobiotechnology.com/content/11/1/40RESEARCH Open AccessMitigating prolonged QT interval in cancer
nanodrug development for accelerated clinical
translation
Amalendu P Ranjan1†, Anindita Mukerjee1†, Lawrence Helson2 and Jamboor K Vishwanatha1*Abstract
Background: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical
evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug
Administration (FDA) has rejected many potential pharmaceutical agents due to QT prolongation effects. Since
drug development and FDA approval takes an enormous amount of time, money and effort with high failure rates,
there is an increased focus on rescuing drugs that cause QT prolongation. If these otherwise safe and potent drugs
were formulated in a unique way so as to mitigate the QT prolongation associated with them, these potent drugs
may get FDA approval for clinical use. Rescuing these compounds not only benefit the patients who need them
but also require much less time and money thus leading to faster clinical translation. In this study, we chose
curcumin as our drug of choice since it has been shown to posses anti-tumor properties against various cancers
with limited toxicity. The major limitations with this pharmacologically active drug are (a) its ability to prolong QT
by inhibiting the hERG channel and (b) its low bioavailability. In our previous studies, we found that lipids have
protective actions against hERG channel inhibition and therefore QT prolongation.
Results: Results of the manual patch clamp assay of HEK 293 cells clearly illustrated that our hybrid nanocurcumin
formulation prevented the curcumin induced inhibition of hERG K+ channel at concentrations higher than the
therapeutic concentrations of curcumin. Comparing the percent inhibition, the hybrid nanocurcumin limited
inhibition to 24.8% at a high curcumin equivalent concentration of 18 μM. Liposomal curcumin could only decrease
this inhibition upto 30% only at lower curcumin concentration of 6 μM but not at 18 μM concentration.
Conclusions: Here we show a curcumin encapsulated lipopolymeric hybrid nanoparticle formulation which could
protect against QT prolongation and also render increased bioavailability and stability thereby overcoming the
limitations associated with curcumin.
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Cardiac safety is very critical for any drug development.
Since drug development often takes many years and re-
quires an investment of millions of dollars to achieve
FDA approval, it becomes critical to determine the car-
diac safety and translational possibilities early in the
development process [1-5]. In the early 1990s, several* Correspondence: jamboor.vishwanatha@unthsc.edu
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stated.marketed drugs were withdrawn due to their arrhythmo-
genic risk. On a standard ECG, these drugs prolonged
the QT interval which is the duration measured from
the beginning of the QRS complex (depolarization of the
cardiac myocytes) to the end of the T wave (completion
of the repolarization phase of the cardiac myocytes). A
prolonged QT interval may potentially induce torsade
des pointes (TdP) which is a form of ventricular ar-
rhythmia [6]. Repolarization of the cardiac action poten-
tial is a result of currents generated by an outward flow
of K+ through the K+ channels. Obstruction of ion flow
in the channel leads to delayed repolarization as evi-
denced by a prolonged QT interval [7]. This led theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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nical Requirements for Registration of Pharmaceuticals
for Human Use to issue the E17 guideline in 2005. This
guideline was directed at the clinical evaluation of QT
interval prolongation and proarrhythmic potential of
non-antiarrhythmic drugs. During drug development
and phase I-II studies, it is important to ascertain the
potential of the drug to cause (a) direct myocyte toxicity,
(b) changes in cardiac repolarization, (c) prolong QT
interval, (d) effects on vascular tone and injury [8], or (e)
induction of life threatening proarrhythmias. The guide-
line required that the effect on cardiac repolarization of
every drug, including anticancer agents, should be evalu-
ated before phase II trials [9].
Several drugs can interfere with hERG (human ether-
a-go-go-related gene) coded potassium channels, which
are responsible for the rapid component of repolarisa-
tion. This drug induced inhibition may ultimately lead to
prolongation of the QT interval [10]. The hERG (human
ether-a-go-go related gene) encodes for the α-subunit of
the ion channel that is responsible for the rapidly acti-
vating delayed rectifier potassium channel IKr (Kv11.1).
The three-dimensional structure of the hERG channel is
still unknown although site-directed mutagenesis data
have provided some insight into its structure [11]. With-
in the hERG channel pore cavity, ion flux and currents
can be modified depending upon the open or closed
states, and by drug interactions at key high affinity drug
binding sites. These sites are the aromatic amino-acid
residues (Y652 and F656) on the inner helices of the
pore. The most important currents mediated by drugs
are the sensitive delayed IKr (rapid) current which repo-
larizes the myocardial cells and the IKs (slow) rectifier
currents are exhibited on the standard ECG as the QT
interval. The corrected current with heart rate is defined
as QTc [7]. This IKr or the hERG current is critical for
ventricular repolarization and inhibition of IKr can in-
duce QT prolongation which may result in life threaten-
ing ventricular arrhythmias [12].
Curcumin is a drug molecule that has an enormous
clinical potential as a potent anti-cancer, anti-oxidant,
anti-inflammatory and anti-bacterial drug in addition to
its many other pharmacological properties. Unfortu-
nately, curcumin has been reported to block the hERG
K+ potassium channel [7,13]. Studies revealed that cur-
cumin inhibited the hERG K+ channel in a concentration
dependent manner with an IC50 as low as 5.5 μM. A low
concentration of 11.4 μM of curcumin resulted in an
80% inhibition of hERG tail current density leading to
prolongation in the QT interval [13]. Since curcumin in-
duces QT prolongation, it is unsafe for clinical transla-
tion unless there are ways to inhibit its QT prolonging
properties. Until now there has been only one study on
QT prolongation caused by curcumin. This particularstudy shows that liposomal formulation of curcumin is
able to prevent QTc prolongation [7]. However, the con-
centration of liposomal curcumin which is able to provide
this protection is still much lower than the therapeutic
concentration.
In the present study, we developed a nanoformulation
of curcumin that may mitigate hERG channel current
inhibition by encapsulating therapeutic concentrations
of curcumin within lipopolymeric hybrid nanoparticles
in order to block the inhibition of hERG K+ channels. A
representation of the same is illustrated in Figure 1. We
believe this would result in a safer clinical product and
FDA approval. Compared to other curcumin nanofor-
mulations, our nanocurcumin formulation provides im-
proved bioavailability and better stability which are
critical for successful scalability and long shelf life. Using
stably transfected Human Embryonic Kidney cells (HEK
293 cells), this study tested the in vitro effects of three
different lipopolymeric hybrid nanocurcumin formula-
tions in comparison to liposomal curcumin and curcu-
min on the potassium-selective IKr current generated in
normoxic conditions.Materials and methods
Materials
E-4031, a class III anti-arrhythmic drug is a synthetic
toxin used solely for research with one clinical exception
[14]. Its mechanism of action is to block the hERG
voltage-gated K+ channels. E-4031, purchased from Sigma-
Aldrich, was selected as a positive control compound for
this study. Three naive HEK293-hERG cells were exposed
to 100 nM E-4031.
Curcumin, 99.2% pure, was synthesized under GMP
conditions by Sabinsa (NJ, USA) and obtained through
SignPath Pharma Inc. The GMP grade liposomal curcumin
was obtained from Polymun GmbH (Vienna, Austria). The
liposomal curcumin were made with a 9:1 ratio of DMPC
(1,2-dimyristoil-sn-glycero-3-phosphocholine) and DMPG
(1,2-dimyristoyl-sn-glycero-3-phospho-rac-[1-glycerol])
with a curcumin content of 6.4 mg/ml.
The concentration of various curcumin nanoformula-
tions and curcumin (6, 12 and 18 μM) were selected
based on predicted human plasma levels. The selected
concentrations reflected a range estimated to exceed the
therapeutic doses and provide valuable predictions of
the effect of curcumin and various nanocurcumin for-
mulations on human cardiac electrophysiology.Formulation of lipopolymeric hybrid curcumin
nanoparticles
Three different formulations of curcumin encapsulated
lipopolymeric hybrid nanoparticles were prepared to



































































Figure 1 Schematic diagram depicting the mitigating of prolonged QT interval using nanodrug.
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Curcumin was dispersed in an organic phase containing
PLGA in acetonitrile. The lipids, DMPC (1,2-dimyristoil-
sn-glycero-3-phosphocholine) and DMPG (1,2-dimyris-
toyl-sn-glycero-3-phospho-rac-[1-glycerol]) were used at
a pre-determined ratio (7:3). There are previous reports
of liposomes composed of the same lipids (i.e. DMPC
and DMPG), which lacked general toxicity and decreased
nystatin toxicity [15]. Hence we chose to use the same
combination of lipids but optimized the ratio in a previous
study to obtain the optimal formulation. DMPG was dis-
solved in double distilled water while DMPC was dis-
solved in 4% ethanol water. Both lipids were then mixed
and heated to 45°C. The organic phase mixture was sub-
sequently added dropwise with constant stirring. The
mixture was stirred for 3 hours on magnetic stirrers to
facilitate evaporation of the organic solvent from the for-
mulation. Once the organic solvent was evaporated, the
mixture was centrifuged thrice at 6000 rpm for 15 minutes
using Amicon filters with a 10 kd cutoff. The nanoparticles
so obtained were resuspended in a 5% sucrose that acts as
a cryoprotectant. Further, the nanoparticle-cryoprotectant
mixture is flash frozen in liquid nitrogen for 5 minutes
and then lyophilized overnight.
Formulation B (HNC-PS): probe sonication
Curcumin was dispersed in an organic phase contai-
ning PLGA in ethyl acetate. The lipids, DMPC (1,2-
dimyristoil-sn-glycero-3-phosphocholine) and DMPG(1,2-dimyristoyl-sn-glycero-3-phospho-rac-[1-glycerol])
were used in the same ratio (7:3). DMPG was dissolved in
double distilled water while DMPC was dissolved in 4%
ethanol water. The lipid mixture and the PLGA-curcumin
solution were mixed and sonicated for 1 minute. Subse-
quently, the nanoparticles were centrifuged at 6000 rpm
for 15 minutes using Amicon filters with a 10kd cutoff
and then washed thrice. The nanoparticles were resus-
pended in a 5% sucrose, flash frozen in liquid nitrogen
and lyophilized overnight.
Formulation C (HNC-PS-C): probe sonication with chitosan
blended polymer
In this protocol, chitosan was added during the formula-
tion of curcumin loaded PLGA nanoparticles using ethyl
acetate by solvent evaporation in order to provide a
positive surface charge to the nanoparticles [16]. Since
lipids mostly carry negative charge, this method leads to
a tighter lipid layer on the surface of the nanoparticles.
The formulation was carried out as described under
probe sonication.
Characterization of lipopolymeric hybrid curcumin
nanoparticles
The lipopolymeric hybrid nanocurcumin from all three
batches were characterized for their drug loading as pre-
viously described. Particle size and zeta potential are
important parameters as they have an effect on both
the intracellular uptake as well as the stability of the
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cles were determined by Nanotrac Particle Size Analyzer
(Mircotrac, Inc., Montgomeryville, PA). Nanoparticles
were characterized for zeta (ζ) potential by using a Zetasi-
zer (ZEN4602, Malvern Instruments, Worchestershire,
UK). The dried nanoparticles were suspended in distilled
Milli Q treated water (pH 7) and measured. Zeta potential
was calculated based on electrophoretic mobilityof the
nanoparticles in aqueous medium. Surface morphology
was determined by Transmission Electron Microscopy
(TEM) as described elsewhere [17]. Further, stability ana-
lysis was also carried out at 4°C for all the three batches of
nanoparticles formulated.
Determination of hERG current inhibition
The compounds tested for hERG current inhibition in-
clude lipopolymeric hybrid nanocurcumin (HNC-NP,
HNC-PS, HNC-PS-C), liposomal curcumin and curcu-
min. E-4031 was selected as the positive control to con-
firm the sensitivity of the test system. This study was
carried out at IPS Therapeutique, Inc., QC, Canada.
Manual patch clamp assay
Whole cell patch-clamp recordings were made at 35 ± 2°C
from HEK 293 cells stably transfected with the hERG
gene. Cells were plated onto 35 mm petri dishes (Falcon)
and maintained in culture with the selective agent G148
(Sigma-Aldrich, St. Louis). Cells were washed twice with
1 mL of hERG external solution containing (mM) NaCl
140, KCl 5, CaCl2 1.8, MgCl2 1, Glucose 10 and HEPES 10
(pH 7.4) followed by the addition of 2 mL of hERG ex-
ternal solution. The petri dish (experimental chamber)
was mounted on the stage of an inverted phase contrast
microscope. A borosilicate glass micropipette (open resis-
tance of 5 to 15 MΩ) pulled with a PMP-102 Program-
mable Micropipette Puller and filled with internal pipette
solution containing (in mM) KCl 140, MgCl2 1, EGTA 5,
HEPES 10, Mg-ATP 4 and sucrose 10 was positioned
above a single cell using an Eppendorf PatchMan micro-
manipulator. The micropipette was lowered to the cell
until a close contact was achieved. The whole-cell config-
uration was then obtained by applying a slight negative
pressure (resistances were measured by a 5-mV square
pulse to be in the GΩ range). Cell capacitance was imme-
diately measured in order to evaluate cell surface area,
using a conversion factor of 1 pF/m2. This cell surface area
was later used to calculate net current density (as opposed
to current amplitude).
Currents were acquired at a rate of 1 kHz, and filtered
using a low-pass 4-pole Bessel filter with the cut-off rate
set at 500 Hz. Baseline condition currents were recorded
using the PClamp 10 acquisition suite (Molecular De-
vices, Sunnyvale, CA) following a 2-minute equilibration
period. Currents were then recorded after 5 minutes ofexposure to each concentration of test compounds or
positive controls (lipopolymeric hybrid nanocurcumin,
liposomal curcumin, curcumin, E-4031). The cells were
stimulated continuously with the following pulse:
Pulses Protocol
Currents were analyzed using the Clampfit 10.2.0.14
module of the pClamp 10.2.0.14 software (Axon Instru-
ment Inc., Foster City, California, USA, (now Molecular
Devices Inc.).
Current run-down and solvent effect correction
All data points have been corrected for solvent effect
and time-dependent current run-down. Current run-
down and solvent effects were measured simultaneously
by applying the experimental design in test-compound
free conditions (dimethyl sulfoxide vehicle) over the same
time frame as was done with the test compounds. The loss
in current amplitude measured during these vehicle con-
trol experiments (representing both solvent effects and
time-dependent run-down) was subtracted from the loss
of amplitude measured in the presence of the test com-
pound. This procedure isolates the effect of the test com-
pound from the effect of the solvent and the inevitable
run-down in current amplitude over time.
Application of test compounds, positive control and
vehicle
Cells were exposed for 5 minutes to each concentration
of compounds in the presence of closed circuit perfusion
(2 mL/min). The cells were allowed 5 minutes for washout
in the presence of a flow-through perfusion (2 mL/min) in
addition to a closed circuit perfusion (2 mL/min). The
positive control (100 nM; E-4031) was added to naive cells
obtained from the same cell line and passage number for
a period of 5 minutes in presence of a closed circuit perfu-
sion (2 mL/min). Cells were under continuous stimulation
of the pulses protocol throughout the experiments and
cell currents were recorded after 5 minutes of exposure to
each condition.
Statistical analysis
Statistical comparisons were made using paired Student’s
t-tests. For the test compounds, the currents recorded
Figure 2 Transmission electron microscopy: A) HNC-NP; B) HNC-PS and C) HNC-PS-C formulations showing smooth and spherical
monodispersed nanoparticles.
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trations were statistically compared to the currents re-
corded in baseline conditions. Currents recorded after
the washouts were compared to the currents measured
after the highest concentration of test compounds. In
the same way, currents recorded after the positive con-
trol was compared to the currents recorded in baseline
conditions. Differences were considered significant when
p ≤0.05.Figure 3 Stability analysis of hybrid nanoparticles at 4°C for
6 days. No significant change in particle size is observed for
any batch.Results and discussion
Formulation and characterization of lipopolymeric hybrid
curcumin nanoparticles
Our results reveal that all three different formulations of
the curcumin encapsulated lipopolymeric hybrid na-
noparticles (HNC-NP, HNC-PS and HNC-PS-C) were
successful. The first formulation (e.g. HNC-NP) was pre-
pared by nanoprecipitation. The other two formulations
(e.g. HNC-PS and HNC-PS-C) were prepared by probe
sonication with or without chitosan. The hybrid nano-
particles were characterized for curcumin content or
drug loading. We observed that the HNC-NP and HNC-
PS-C formulations had a curcumin loading of 18 ±
0.8 μg/mg and 18.2 ± 1.2 μg/mg respectively. The HNC-
PS formulation had a lower curcumin content of 6.8 ±
0.74 μg/mg. The particle sizes of the nanoparticles for the
different batches were 113.9 ± 8.3, 147.2 ± 15.7, 162.2 ±
12.4 nm respectively. The zeta potential of the batches
was found to be −24.5 ± 1.7 mV for HNC-NP, -24.8 ±
2.9 mV for HNC-PS and −21.1 ± 2.3 mV for HNC-PS-C.
The slight change in the HNC-PS-C can be explained by
the incorporation of chitosan which may impart some
positive charge. The transmission electron microscopy
(TEM) images show the surface morphology of the hybrid
nanoparticles to be smooth and spherical (Figure 2A-C).
The stability analysis was carried out for all the three
batches of nanoparticles formulated at 4°C for 6 days.
Results (Figure 3) show no significant change in particle
size of the nanoparticles for the entire duration of thestudy ensuring that the hybrid nanoparticle are stable for
atleast 6 days at 4°C.
Effect of different formulations on whole-cell IKr hERG
currents
The hERG assay or the Manual Patch Clamp assay is
used to assess the potential of a compound to interfere
with the rapidly activating delayed-rectifier potassium
channel. This inital study used stably transfected Human
Embryonic Kidney cells (HEK 293 cells) in normoxic
conditions to quantify the in vitro effects of lipopo-
lymeric hybrid nanocurcumin formulations, (HNC-NP,
HNC-PS and HNC-PS-C), liposomal curcumin and free
curcumin on the potassium-selective IKr current. The
study design was based on the current International
Conference on Harmonisation (ICH) Harmonized Tri-
partite Guidelines [9].
Whole-cell currents elicited during a voltage pulse
were recorded in baseline conditions and following the
application of the selected concentrations of test com-
pounds. Currents were also recorded following a wash-
out period. The cells were depolarized for one second
from the holding potential (−80 mV) to a maximum
value of +40 mV, starting at −40 mV and progressing in
10 mV increments. The membrane potential was then
Table 1 Effect of tested compounds on hERG current density at +20 mV (I+20)
Compound tested Statistically significant









HNC-NP 18 24.8 No n/a Yes
HNC-PS 6 40.2 No n/a Yes
HNC-PS-C 6 25.2 No n/a Yes
Curcumin 12 77.8 No 8.5 Yes
Liposomal curcumin 6 only 30 No n/a No
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turned to −80 mV. Whole-cell tail current amplitude
was measured at a holding potential of −55 mV, fol-
lowing activation of the current from −40 to +40 mV.
Current amplitude was measured at the maximum (peak)
of this tail current. Current density was obtained by divi-
ding current amplitude by cell capacitance measured prior
to capacitive transient minimization. Each of the test
compounds was analyzed at three different concentra-
tions (6, 12 and 18 μM) for hERG current inhibition. The
effect of test compounds on hERG current density is
shown in Table 1. The results of the Manual Patch Clamp
assay reveal that lipopolymeric hybrid nanocurcumin for-
mulations were able to protect against the inhibition of
hERG current caused by curcumin. Out of the three hy-
brid nanocurcumin formulations, formulation HNC-NP
was found to impart the best protection as seen in
Figure 4. At a concentration of 18 μM of curcumin
equivalent, the HNC-NP formulation caused the least
inhibition of current density (24.8% inhibition) followed
by HNC-PS-C (25.2% inhibition) when compared toFigure 4 hERG tail current density averages obtained by measuring t
and in the presence of curcumin, Formulation HNC-NP, Formulation H
curcumin concentrations were always 6.0, 12 and 18 μM. A: Current density
current density, and corrected for time and solvent effects. Statistical comp
levels were made using repeat paired Student’s t-tests (*). Differences were
hERG tail currents inhibition at the higher concentration of curcumin and h77.8% inhibition caused by curcumin alone. Paired stu-
dent’s t-tests confirmed that the difference in normalized
current density measured at baseline and in the presence
of 18 μM of lipopolymeric hybrid nanocurcumin reached
the selected threshold for statistical significance (p ≤ 0.05).
The liposomal curcumin formulation, at a curcumin con-
centration of 6 μM, induced a statistically significant in-
hibition of the hERG tail current (30%) at I+20 (n = 3) (not
included in figure). E-4031 (a positive control) induced a
significant inhibition of the current amplitude (81.8%) for
I+20 at a concentration of 100 nM. Additionally, poly
(lactic-coglycolic acid) (PLGA), at concentrations ran-
ging from 0.52 to 29.81 μg/mL did not cause a statis-
tically significant inhibition of the hERG tail current
density for I+20 (n = 3). This result implies that formu-
lation HNC-NP reduced the hERG current inhibition
by 68.1% at a concentration as high as 18 μM which repre-
sents a significant protection of the hERG channel current
inhibition caused by curcumin. To confirm the rever-
sal effect of the test compounds, cells exposed to the high-
est concentration of curcumin equivalent formulationhe hERG tail peak amplitude at 20 mV in baseline conditions
NC-PS and Formulation HNC-PS-C hybrid nanocurcumin. The
was measured from 7 cells, averaged, normalized against baseline
arisons between post-drug exposure and baseline current density
considered significant when p≤ 0.05. B: Voltage dependency of the
ybrid nanoformulations tested (18 μM).
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The current measured after the washout period was not
statistically different when compared to the current fol-
lowing exposure to the highest concentration of the com-
pounds suggesting that the effect of these compounds was
not reversible at this time point.
It has been previously reported that curcumin inter-
acts with the alpha subunit of the K+ channel which
forms the pore of the hERG channel [7]. It is this sub-
unit which is encoded by the hERG gene. Maati et al
reported a similar study showing that a curcuminoid
mixture containing 78% curcumin brought about com-
parable inhibition of the hERG current [18]. A study by
Helson et al demonstrated that liposome may have a
protective effect against the inhibitory interactions of ac-
tive compounds with channel drug receptor sites allow-
ing more normal gating kinetics to occur. However, they
could not confirm whether the changes in gating ki-
netics were due to a direct interaction of curcumin with
the pore-forming peptides, or whether a change in lipid
packing in proximity of the hERG channel resulted in
decreased inhibition [7]. However, the concentration of
liposomal curcumin which is able to provide this protec-
tion was much lower than the therapeutic concentration
of curcumin and the liposomal formulation was found
to be stable only at -20°C [7].
The results of the present study (Table 1) confirm that
the curcumin (diferuloylmethane) molecule exhibits pro-
minent IKr inhibition as reported by other research groups
[7,13]. In the present study, our formulation of lipopo-
lymeric hybrid nanocurcumin formulation was concep-
tualized based on the protective effects of liposomes on
curcumin dependent inhibition of the hERG current. Fur-
ther, the introduction of a polymer layer in the hybrid for-
mulation imparted much needed stability and tunability to
the formulation. The manual patch clamp assay of HEK
293 cells clearly illustrated that this hybrid nanocurcumin
formulation prevented the curcumin induced inhibition of
hERG K+ channel at concentrations higher than the thera-
peutic concentrations of curcumin. Liposomal curcumin,
on the other hand, could only decrease this inhibition at
lower curcumin concentration (6 μM). Comparing the
percent inhibition, the hybrid nanocurcumin limited in-
hibition to 24.8% at a high curcumin equivalent concen-
tration of 18 μM (n = 3; statistically significant). This is
substantially less than the inhibition (30%) brought about
by liposomal curcumin at one third the concentration
(6 μM curcumin equivalent). There remains a need to de-
termine whether the changes in gating kinetics were
brought about due to direct interaction of curcumin with
pore-forming peptides, or whether a change in lipid pack-
ing in proximity of the hERG channel resulted in de-
creased inhibition. Moreover, the present formulation
provided improved bioavailability [19] (data not shown)and as expected, this formulation was stable both at 4°C
for an extended period of time.
Conclusions
The inhibition of the IKr current induced by curcumin is
mitigated when curcumin is incorporated within a lipo-
polymeric hybrid nanoparticle formulation prior to ex-
posure. Such a formulation not only protects inhibition
of hERG channel current induced by curcumin but also
provides improved bioavailability and stability. Similar hy-
brid formulations may be used for other QT-prolonging
drugs to mitigate prolonged QT effects in vitro. Further
testing of the hybrid nanoformulation with other QT-
prolonging drugs in animal models with QT-prolongation
may lead to faster clinical translation and FDA approval of
such cardiotoxic yet pharmacologically potent drugs.
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